Navigation Links
26S Proteasome Fraction Extract from GeneTex

Products26S Proteasome Fraction Extract from GeneTex
Company GeneTex
Item 26S Proteasome Fraction Extract
Price $380.00
Description Proteolytic degradation is critical to the maintenance of appropriate levels of short-lived and regulatory proteins as important and diverse as those involved in cellular metabolism, heat shock and stress response, antigen presentation, modulation of cell surface receptors and ion channels, cell cycle regulation, transcription, and signalling factors. The ubiquitin-proteasome pathway deconstructs most proteins in the eukaryotic cell cytosol and nucleus. Others are degraded via the vacuolar pathway which includes endosomes, lysosomes, and the endoplasmic reticulum. The 26S proteasome is an ATP-dependent, multisubunit (~31), barrel-shaped molecular machine with an apparent molecular weight of ~2.5 MDa. It consists of a 20S proteolytic core complex which is crowned at one or both ends by 19S regulatory subunit complexes. The 19S regulatory subunits recognize ubiquitinated proteins and play an essential role in unfolding and translocating targets into the lumen of the 20S subunit. An enzymatic cascade is responsible for the attachment of multiple ubiquitin molecules to lysine residues of proteins targeted for degradation. Several genetic diseases are associated with defects in the ubiquitin-proteasome pathway. Some examples of affected proteins include those linked to cystic fibrosis, Angelmans syndrome, and Liddle syndrome. GTX80879 is the partially purified fraction containing 26S proteasome and none of the conjugation enzymes (E1, E2s, E3s). Preferred for the degradation of pre-formed ubiquitin-protein conjugates by the 26S proteasome since highly purified 26S is costly and more labile.

  • Type: Proteins and peptides
  • Form: 0.5 mg/ml in 50 mM HEPES, pH 7.6, 1 mM Mg-ATP, 150 mM NaCl and 10% glycerol.
Info GeneTexGeneTex
14785 Omicron Dr. Suite101
San Antonio, TX 78245
Customer Service: (877) 436-3839
Fax Number: (210) 677-8843
Web Site: http://www.genetex.com
NOTE: Price information is approximate list price and actual prices may vary.

Related biology products :

1. Ubiquitin/Proteasome Fraction II Extract from GeneTex
2. 20S Proteasome Fluorometric (AMC) Assay Kit from CHEMICON
3. 26S Proteasome Fraction Extract from GeneTex
4. Mouse Anti-20S Proteasome alpha1, 2, 3, 5, 6, & 7-Subunits Monoclonal Antibody, Unconjugated, Clone MCP231 from Calbiochem
5. ProteomeLab PF 2D Protein Fractionation System from Beckman Coulter
6. UBC Fractions Extract from GeneTex
7. Ubiquitin Fraction I from ABR-Affinity BioReagents
8. Ubiquitin Fraction I Extract from GeneTex
9. FractionPREP Cell Fractionation Kit from BioVision
10. cDNA Size Fractionation Columns from Invitrogen
11. ZOOM® IEF Fractionator from Invitrogen
... Genome-pULSe Kit delivers a novel procedure for ... labeling of whole genome DNA from small ... provide a quick and highly reproducible amplification ... consists of a REPLI-g Mini Kit module ...
... Introduction of a protein into cells permits ... signaling pathways, apoptotic pathways, and transcription factor-mediated ... studying the effects of a specific protein ... the protein directly into the cell. ProteoJuice ...
... ST-190-XY is an automated instrument with a ... in real-time using light or fluorescence microscopy. ... muscle, and fibroblast cells can be simulated ... X and Y axis of our strain ...
... Our Smart Solutions has now entered the ... (HCS) by partnering up with Cellomics, Inc. ... the integration of Beckman Coulter‘s automated solutions ... deeper biological information at the sub-cellular level. ...
Biology Products:
(Date:10/16/2014)... thinking on how the bowel lining develops and, in ... cancer starts. , The researchers produced evidence that stem ... that are a feature of the bowel lining, and ... development, a controversial finding as scientists are still divided ... technologies, Dr Chin Wee Tan and Professor Tony Burgess ...
(Date:10/16/2014)... respiratory tract infections and worldwide claims the lives ... and Ghent University have succeeded in developing a ... infection. , Xavier Saelens (VIB/UGent): "We discovered ... for the development of a novel approach to ... in numerous small children and elderly people." , ...
(Date:10/16/2014)... 16, 2014 NXT-ID, Inc. (NASDAQ: ... biometric authentication company focused on the growing mobile commerce ... including Wocket™, the Smart Wallet, at the 13 th ... a leading global conference on the intersection of technology ... Mark Anderson , founder and publisher of the Strategic ...
Breaking Biology News(10 mins):Cryptic clues drive new theory of bowel cancer development 2New perspectives for development of an RSV vaccine 2NXT-ID Inc. to Present at 13th Annual FiRe Conference 2NXT-ID Inc. to Present at 13th Annual FiRe Conference 3
... honors four leaders in biomedical and health informatics ... Annual Symposium, Oct. 22-26, an event expected to ... over the coming week. The Signature Awards highlight ... sector have had significant, positive impact. , ...
... 20 OCTOBER 2011 EMBO today acknowledges the outstanding ... by awarding them life-long EMBO membership. Election to ... excellence and the exceptional achievements made by a life ... 1,500 of the best researchers in Europe and around ...
... COLUMBIA, Mo. The face and brain develop ... the embryo and continuing through adolescence. Now, University of ... characteristics of children with autism compared to those of ... the origins of autism. "There is ...
Cached Biology News:AMIA honors informatics professionals who are improving health, changing the world 2AMIA honors informatics professionals who are improving health, changing the world 346 outstanding life scientists elected to EMBO membership 2Autistic facial characteristics identified 2
(Date:10/25/2014)... , October 24, 2014 Investor-Edge ... (NASDAQ: CYTR ), Vertex Pharmaceuticals Inc. (NASDAQ: ... ALXN ), Peregrine Pharmaceuticals Inc. (NASDAQ: ... on these five companies can be accessed at: ... October 23, 2014, ended on a positive note as ...
(Date:10/22/2014)... , Oct. 22, 2014  Actavis plc (NYSE: ... company, and Rhythm, a biopharmaceutical company, today announced that ... Rhythm,s wholly owned subsidiary, Rhythm Health, Inc., which is ... treatment of diabetic gastroparesis and other GI functional disorders. ... 2 trial of relamorelin for the treatment of diabetic ...
(Date:10/22/2014)... 2014 WriteResult, LLC – a ... been working with a team of researchers from Yale ... Community Farming Collaborative to provide electronic questionnaire data collection ... study, which started in May, aims to evaluate the ... weekly exposure to and participation in urban agriculture to ...
(Date:10/22/2014)... , Oct. 22, 2014   Synthetic Biologics, Inc. ... pathogen-specific therapies for serious infections and diseases, announced today ... a Notice of Allowance for a composition of matter ... C. difficile program, SYN-004. This is Synthetic Biologics, ... the U.S. and adds to the Company,s extensive ...
Breaking Biology Technology:Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 2Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 3Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 4Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 5Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 2Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 3Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 4Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 5myPROpad™ Topic of Panel Discussion at the Yale Food Systems Symposium 2myPROpad™ Topic of Panel Discussion at the Yale Food Systems Symposium 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 2Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 4